Prognostic Value of the Metabolic and Volumetric Parameters of ¹¹C-Methionine Positron-Emission Tomography for Gliomas: A Systematic Review and Meta-Analysis

References

1. 1.↵
   2. Rigau V,
   3. Zouaoui S,
   4. Mathieu-Daudé H, et al

   ; Société Française de Neuropathologie (SFNP), Société Française de Neurochirurgie (SFNC), Club de Neuro-Oncologie of the Société Française de Neurochirurgie (CNO-SFNC), Association des Neuro-Oncologues d'Expression Française (ANOCEF). French brain tumor database: 5-year histological results on 25 756 cases. Brain Pathol 2011;21:633–44 doi:10.1111/j.1750-3639.2011.00491.x pmid:21554472

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Ostrom QT,
   3. Gittleman H,
   4. Liao P, et al

   . CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol 2014;16(Suppl 4):iv1–63 doi:10.1093/neuonc/nou223 pmid:25304271

   CrossRefPubMed
3. 3.↵
   2. Behin A,
   3. Hoang-Xuan K,
   4. Carpentier AF, et al

   . Primary brain tumours in adults. Lancet 2003;361:323–31 doi:10.1016/S0140-6736(03)12328-8 pmid:12559880

   CrossRefPubMedWeb of Science
4. 4.↵
   2. van den Bent MJ,
   3. Vogelbaum MA,
   4. Wen PY, et al

   . End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's criteria. J Clin Oncol 2009;27:2905–08 doi:10.1200/JCO.2009.22.4998 pmid:19451418

   FREE Full Text
5. 5.↵
   2. Hutterer M,
   3. Hattingen E,
   4. Palm C, et al

   . Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients. Neuro Oncol 2015;17:784–800 doi:10.1093/neuonc/nou322 pmid:25543124

   CrossRefPubMed
6. 6.↵
   2. Galldiks N,
   3. Rapp M,
   4. Stoffels G, et al

   . Response assessment of bevacizumab in patients with recurrent malignant glioma using [¹⁸F]fluoroethyl-L-tyrosine PET in comparison to MRI. Eur J Nucl Med Mol Imaging 2013;40:22–33 doi:10.1007/s00259-012-2251-4 pmid:23053325

   CrossRefPubMed
7. 7.↵
   2. Galldiks N,
   3. Langen K

   . Applications of PET imaging of neurological tumors with radiolabeled amino acids. Q J Nucl Med Mol Imaging 2015;59:70–82 pmid:25517079

   PubMed
8. 8.↵
   2. Glaudemans AW,
   3. Enting RH,
   4. Heesters MA, et al

   . Value of ¹¹C-methionine PET in imaging brain tumours and metastases. Eur J Nucl Med Mol Imaging 2013;40:615–35 doi:10.1007/s00259-012-2295-5 pmid:23232505

   CrossRefPubMed
9. 9.↵
   2. Terakawa Y,
   3. Tsuyuguchi N,
   4. Iwai Y, et al

   . Diagnostic accuracy of ¹¹C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med 2008;49:694–99 doi:10.2967/jnumed.107.048082 pmid:18413375

   Abstract/FREE Full Text
10. 10.↵
    2. Kim S,
    3. Chung JK,
    4. Im SH, et al

    . ¹¹C-methionine PET as a prognostic marker in patients with glioma: comparison with ¹⁸F-FDG PET. Eur J Nucl Med Mol Imaging 2005;32:52–59 doi:10.1007/s00259-004-1598-6 pmid:15309332

    CrossRefPubMed
11. 11.↵
    2. Cicuendez M,
    3. Lorenzo-Bosquet C,
    4. Cuberas-Borrós G, et al

    . Role of [¹¹C] methionine positron emission tomography in the diagnosis and prediction of survival in brain tumours. Clin Neurol Neurosurg 2015;139:328–33 doi:10.1016/j.clineuro.2015.10.035 pmid:26588352

    CrossRefPubMed
12. 12.↵
    2. Watanabe A,
    3. Muragaki Y,
    4. Maruyama T, et al

    . Usefulness of ¹¹C-methionine positron emission tomography for treatment-decision making in cases of non-enhancing glioma-like brain lesions. J Neurooncol 2016;126:577–83 doi:10.1007/s11060-015-2004-x pmid:26612734

    CrossRefPubMed
13. 13.↵
    2. Boellaard R,
    3. Krak NC,
    4. Hoekstra OS, et al

    . Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med 2004;45:1519–27 pmid:15347719

    Abstract/FREE Full Text
14. 14.↵
    2. Kang CM,
    3. Lee SH,
    4. Hwang HK, et al

    . Preoperative volume-based PET parameter, MTV2. 5, as a potential surrogate marker for tumor biology and recurrence in resected pancreatic cancer. Medicine 2016;95:e2595 doi:10.1097/MD.0000000000002595 pmid:26945350

    CrossRefPubMed
15. 15.↵
    2. Hyun SH,
    3. Choi JY,
    4. Shim YM, et al

    . Prognostic value of metabolic tumor volume measured by ¹⁸F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. Ann Surg Oncol 2010;17:115–22 doi:10.1245/s10434-009-0719-7 pmid:19826877

    CrossRefPubMedWeb of Science
16. 16.↵
    2. La TH,
    3. Filion EJ,
    4. Turnbull BB, et al

    . Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009;74:1335–41 doi:10.1016/j.ijrobp.2008.10.060 pmid:19289263

    CrossRefPubMed
17. 17.↵
    2. Kim Y-i,
    3. Paeng JC,
    4. Cheon GJ, et al

    . Prediction of posttransplantation recurrence of hepatocellular carcinoma using metabolic and volumetric indices of ¹⁸F-FDG PET/CT. J Nucl Med 2016;57:1045–51 doi:10.2967/jnumed.115.170076 pmid:26985057

    Abstract/FREE Full Text
18. 18.↵
    2. Fonti R,
    3. Larobina M,
    4. Del Vecchio S, et al

    . Metabolic tumor volume assessed by ¹⁸F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma. J Nucl Med 2012;53:1829–35 doi:10.2967/jnumed.112.106500 pmid:23071351

    Abstract/FREE Full Text
19. 19.↵
    2. Berghmans T,
    3. Dusart M,
    4. Paesmans M, et al

    ; European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 2008;3:6–12 doi:10.1097/JTO.0b013e31815e6d6b pmid:18166834

    CrossRefPubMedWeb of Science
20. 20.↵
    2. Zhao Q,
    3. Feng Y,
    4. Mao X, et al

    . Prognostic value of fluorine-18-fluorodeoxyglucose positron emission tomography or PET-computed tomography in cervical cancer: a meta-analysis. Int J Gynecol Cancer 2013;23:1184–90 doi:10.1097/IGC.0b013e31829ee012 pmid:23851677

    CrossRefPubMed
21. 21.↵
    2. Parmar MK,
    3. Torri V,
    4. Stewart L

    . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815–34 pmid:9921604

    CrossRefPubMedWeb of Science
22. 22.↵
    2. Higgins J,
    3. Thompson SG,
    4. Deeks JJ, et al

    . Measuring inconsistency in meta-analyses. BMJ 2003;327:557–60 doi:10.1136/bmj.327.7414.557 pmid:12958120

    FREE Full Text
23. 23.↵
    2. Egger M,
    3. Davey Smith GD,
    4. Schneider M, et al

    . Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34 doi:10.1136/bmj.315.7109.629 pmid:9310563

    Abstract/FREE Full Text
24. 24.↵
    2. Kaschten B,
    3. Stevenaert A,
    4. Sadzot B, et al

    . Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 1998;39:778–85 pmid:9591574

    Abstract/FREE Full Text
25. 25.↵
    2. Ribom D,
    3. Eriksson A,
    4. Hartman M, et al

    . Positron emission tomography (11)C-methionine and survival in patients with low-grade gliomas. Cancer 2001;92:1541–49 pmid:11745233

    CrossRefPubMedWeb of Science
26. 26.↵
    2. De Witte O,
    3. Goldberg I,
    4. Wikler D, et al

    . Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg 2001;95:746–50 doi:10.3171/jns.2001.95.5.0746 pmid:11702862

    CrossRefPubMedWeb of Science
27. 27.↵
    2. Van Laere K,
    3. Ceyssens S,
    4. Van Calenbergh F, et al

    . Direct comparison of ¹⁸F-FDG and ¹¹C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging 2005;32:39–51 doi:10.1007/s00259-004-1564-3 pmid:15309329

    CrossRefPubMedWeb of Science
28. 28.↵
    2. Nariai T,
    3. Tanaka Y,
    4. Wakimoto H, et al

    . Usefulness of L-[methyl-11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg 2005;103:498–507 doi:10.3171/jns.2005.103.3.0498 pmid:16235683

    CrossRefPubMedWeb of Science
29. 29.↵
    2. Ribom D,
    3. Smits A

    . Baseline ¹¹C-methionine PET reflects the natural course of grade 2 oligodendrogliomas. Neurol Res 2005;27:516–21 doi:10.1179/174313213X13789811969265 pmid:15978178

    CrossRefPubMed
30. 30.↵
    2. Galldiks N,
    3. Kracht LW,
    4. Burghaus L, et al

    . Use of ¹¹C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. Eur J Nucl Med Mol Imaging 2006;33:516–24 doi:10.1007/s00259-005-0002-5 pmid:16450140

    CrossRefPubMed
31. 31.↵
    2. Smits A,
    3. Westerberg E,
    4. Ribom D

    . Adding ¹¹C-methionine PET to the EORTC prognostic factors in grade 2 gliomas. Eur J Nucl Med Mol Imaging 2008;35:65–71 doi:10.1007/s00259-007-0531-1 pmid:17710394

    CrossRefPubMed
32. 32.↵
    2. Galldiks N,
    3. Dunkl V,
    4. Kracht LW, et al

    . Volumetry of [¹¹C]-methionine positron emission tomographic uptake as a prognostic marker before treatment of patients with malignant glioma. Mol Imaging 2012;11:516–27 pmid:23084252 pmid:23084252

    PubMed
33. 33.↵
    2. Singhal T,
    3. Narayanan TK,
    4. Jacobs MP, et al

    . ¹¹C-methionine PET for grading and prognostication in gliomas: a comparison study with ¹⁸F-FDG PET and contrast enhancement on MRI. J Nucl Med 2012;53:1709–15 doi:10.2967/jnumed.111.102533 pmid:23055534

    Abstract/FREE Full Text
34. 34.↵
    2. Kobayashi K,
    3. Hirata K,
    4. Yamaguchi S, et al

    . Prognostic value of volume-based measurements on (11)C-methionine PET in glioma patients. Eur J Nucl Med Mol Imaging 2015;42:1071–80 doi:10.1007/s00259-015-3046-1 pmid:25852010

    CrossRefPubMed
35. 35.↵
    2. Yoo MY,
    3. Paeng JC,
    4. Cheon GJ, et al

    . Prognostic value of metabolic tumor volume on (11)C-methionine PET in predicting progression-free survival in high-grade glioma. Nucl Med Mol Imaging 2015;49:291–97 doi:10.1007/s13139-015-0362-0 pmid:26550048

    CrossRefPubMed
36. 36.↵
    2. Takano K,
    3. Kinoshita M,
    4. Arita H, et al

    . Diagnostic and prognostic value of 11C-methionine PET for nonenhancing gliomas. AJNR Am J Neuroradiol 2016;37:44–50 doi:10.3174/ajnr.A4460 pmid:26381556

    Abstract/FREE Full Text
37. 37.↵
    2. Jung TY,
    3. Min JJ,
    4. Bom HS, et al

    . Prognostic value of post-treatment metabolic tumor volume from ¹¹C-methionine PET/CT in recurrent malignant glioma. Neurosurg Rev 2017;40:223–29 doi:10.1007/s10143-016-0748-1 pmid:27282449

    CrossRefPubMed